Biotech News

Bexsero (4CMenB) receives positive CHMP opinion for one-dose Meningitis B booster for 10+ year olds

GSK plc (GSK)GSK plcConference / presentation

13 November 2026

Issued: London, UK

For media and investors only

Download (PDF - 193.3KB)

Recommendation based on data showing immune memory established following vaccination in infancy can be boosted up to 19 years later 1

Once approved, the single-dose booster could help vaccination programmes maintain protection into adolescence, when disease incidence reaches a second peak 2

GSK plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended updating the Bexsero label to include a single booster dose for individuals aged 10 years and older who were previously vaccinated at least two years earlier with Bexsero . The recommendation is supported by data showing that immune memory established following primary vaccination in infancy can be boosted with a single dose up to 19 years later 1 .

Sanjay Gurunathan, Senior Vice President, R&D Vaccines & Infectious Diseases, GSK, said: “As the first generation of children vaccinated against MenB in infancy reaches adolescence, today’s positive CHMP opinion supports maintaining protection with a single booster dose during a second period in life of increased disease risk. If adopted, adolescent boosters could help reduce the overall burden of Invasive Meningococcal Disease (IMD) in countries with established infant MenB programmes”.

While Invasive Meningococcal Disease (IMD) is uncommon, it can progress rapidly and become life-threatening 3 . Disease incidence is highest in infants and young children, with a second peak in adolescents and young adults 2 . Adolescents are more likely to catch or pass on these bacteria because they often spend more time socialising, live closely with others, and may share personal items 4 . In Europe, serogroup B is the leading cause of invasive meningococcal disease in all age groups under 65 years 2 .

The CHMP’s positive opinion is based on data from Men-B-096, a Phase IIIb open label, multi-centre study which assessed the immune response and safety of a single booster dose of Bexsero in healthy individuals aged 10-20 years who previously completed their primary vaccination series with Bexsero . The study met its primary endpoint. The safety and reactogenicity of a single booster dose is consistent with the known safety profile of Bexsero in this age group.

About Men-B-096

Men-B-096 is a Phase IIIb, open label, multi-centre study assessing the immune response and safety of a single dose of Bexsero in healthy children aged 10-20 years. The study enrolled 312 participants across Finland, Italy, Spain and the UK, including 234 who had received Bexsero during infancy and 78 who had not previously received a meningococcal B vaccine. The primary endpoint was to assess the superiority of the immune response to a single booster dose in previously vaccinated participants compared with a first dose in adolescents who hadn’t received a MenB vaccine in the past.

About invasive meningococcal disease (IMD)

IMD is an uncommon but serious infection caused by Neisseria meningitidis that can present as meningitis and/or septicaemia (blood poisoning). Although anyone can develop the disease, incidence is highest among infants and young children, with a second peak in adolescents and young adults 2 . IMD can progress rapidly and may result in death or long-term complications despite treatment. 5,6

About Bexsero (4CMenB)

Bexsero is registered in 61 countries for the prevention of Invasive Meningococcal Disease (IMD) caused by Neisseria meningitidis serogroup B. In Europe, it is included in 15 national and/or regional immunisation programmes for infants, and 3 national immunisation programmes for adolescents, with additional infant vaccination programmes funded at a regional level in some countries 7 . Around 140 million doses of Bexsero have been distributed globally since 2015 8 .

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com .

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q3 Results for 2026.

References

Icardi G, Martinón-Torres F, Salamanca de la Cueva I, et al. A single adolescent dose of 4CMenB effectively boosts immune responses up to 19 years after priming in infancy: Results from a phase 3b, open-label, multicenter study. Presented at the International Pathogenic Neisseria Conference (IPNC), Busselton, Western Australia, Australia, 13-17 September 2026. Abstract 141317.

European Centre for Disease Prevention and Control. Invasive meningococcal disease - Annual Epidemiological Report for 2024. Stockholm: ECDC; 2026. Accessed November 2026. https://www.ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2024

European Centre for Disease Control and Prevention. Disease information about meningococcal disease, 28 November 2023. Available at: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet . Accessed November 2026.

Centers for Disease Control and Prevention. Risk Factors for Meningococcal Disease. Available at: https://www.cdc.gov/meningococcal/risk-factors/index.html . Accessed November 2026

Thompson MJ, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.

McMillan M, McDonough J, Angliss M, Buttery J, Saunders L, Mathew SM, Shaw D, Gordon D, Warner MS, Nelson R, Hannah R, Marshall HS. Exploring the Health-Related Quality of Life and the Lived Experience of Adolescents Following Invasive Meningococcal Disease. Healthcare (Basel). 2024 May 24;12(11):1075. doi: 10.3390/healthcare12111075. PMID: 38891151; PMCID: PMC11172222.

GSK Data on file, REF-343997. Bexsero is included in 15 national immunisation programmes for infants, and 3 national immunisation programmes for adolescents

GSK Data on file, REF-310855. 140 million doses shipped from 2015 to October 2025.

Related news

GSKGSK plc2026-11-17 18:50 EST

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

CRSPCRISPR Therapeutics2026-11-09 14:16 EST

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026

GSKGSK plc2026-10-23 23:00 EST

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

KURAKura Oncology2026-11-13 17:33 EST

Kura Oncology to Participate in Two Investor Conferences in November

CRSPCRISPR Therapeutics2026-11-10 13:30 EST

CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

NTLAIntellia2026-11-10 13:00 EST

Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

MMSIMerit Medical2026-11-05 14:25 EST

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

GSK plc

Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...

Recent company news

Stock data

Close
47.82 USD
Market cap
98.26B USD
Exchange
NYSE
Sector
Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
Location
United States